Gibco™ Recombinant Human Insulin AOP

Features of Gibco rHu Insulin AOF include:

• Supports cell growth and productivity across CHO, HEK293, Hybridoma, VERO, and stem cell systems
• Manufactured using a fully animal origin–free (AOF), GMP-compliant process to align with USP and EP regulatory expectations and minimize contamination sources
• Designed to promote lot-to-lot consistency, supporting reproducible bioproduction results
• Enables efficient scale-up with globally validated supply assurance and adherence to GMP principles.
• Adaptable to your process needs with customizable volumes and flexible packaging options

Gibco rHu Insulin AOF is produced using advanced recombinant DNA technology, helping ensure exceptional purity, performance stability, and elimination of animal-derived materials. It meets USP and EP grade standards, aligning with global regulatory expectations for therapeutic and vaccine manufacturing.

Validated over years by our media development teams, Gibco rHu Insulin AOF is manufactured under the same stringent Gibco quality and testing standards trusted by scientists globally. Its reliable global supply chain, documented traceability, and scalable production formats make it a low-risk, high-performance option for modern bioproduction without the complexities associated with animal-origin (AO) materials.

Bring Gibco validated performance into your own bioprocess. Contact us to learn how our high-value Gibco rHu Insulin AOF can help enhance your productivity and reduce process risk compared to AO-derived.

As a critical growth factor, insulin regulates glucose uptake and metabolism to promote strong cell viability, growth, and protein expression in serum-free and chemically defined systems. It is ideal for bioreactor-based antibody production (CHO, HEK, NS0, Hybridoma and myeloma cells), viral vector manufacturing (HEK293, VERO), and stem cell expansion, where consistency, purity, and low contamination risk are key.